U.S. stock futures advanced on Friday as investors awaited the December jobs report and the Supreme Court's ruling on Trump's tariffs. Major indices showed modest gains with SPY and QQQ trading higher in premarket. Key movers included General Motors facing EV investment losses, Tilray surging on earnings beats, Offerpad jumping on Trump's housing proposal, and Rio Tinto declining amid merger talks with Glencore.

KalVista Pharmaceuticals launched EKTERLY, its first oral treatment for hereditary angioedema, generating $1.4 million in Q1 FY2026 revenue. The launch was accompanied by increased commercialization expenses and a widened net loss, reflecting the company's transition to commercial operations.

The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.

The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares rose 0.4% to close at $322.44 on Tuesday. See how other analysts view this stock. Piper Sandler boosted Shopify Inc. (NYSE: SHOP) price target from $56 to $63. Piper Sandler analyst Clarke Jeffries maintained an Underweight rating. Shopify shares fell 13.4% to close at $77.18 on Tuesday. See how other analysts view this stock. Needham boosted the price target for SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) from $62 to $70. Needham analyst Mayank Tandon maintained a Buy rating. SS&C Technologies shares fell 1.8% to close at $60.15 on Tuesday. See how other analysts view this stock. JP Morgan raised Bruker Corporation ...

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. KalVista Pharmaceuticals The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish P Shah acquired a total of 86,048 shares an ...

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Vera Therapeutics The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Maha Katabi acquired a total of 161,290 shares an average price of $31.00. To acquire these shares, it cost around $5 million. What’s Happening: Vera Therapeutics priced its upsized public offering of ...

Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. KalVista Pharmaceuticals The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish Shah acquired a total of 91,804 shares an ...

Although U.S. stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Talos Energy The Trade: Talos Energy Inc. (NYSE: TALO) 10% owner Control Empresarial de Capitales S.A. de C.V. acquired a total of 19,658,119 shares an average price of $11.70. To acquire these shares, it cost around $230 million. What’s Happening: ...

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. KalVista Pharmaceuticals The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish Shah acquired a ...

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. STAAR Surgical The Trade: STAAR Surgical Company (NASDAQ: STAA) 10% owner Neal Bradsher acquired a total of 4,042 shares an average price of $27.11. To acquire these shares, it cost around $109,570. What’s Happening: STAAR Surgical issued preliminary fourth-quarter and FY23 net ...

Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. STAAR Surgical The Trade: STAAR Surgical Company (NASDAQ: STAA) 10% owner ...